Veryan Medical

What Veryan Medical does

Veryan Medical Limited is a UK-based medical device company that designs, develops, and commercializes the BioMimics 3D Vascular Stent System, a peripheral self-expanding nitinol stent with a patented 3D helical centerline geometry. Originating as a 2005 Imperial College London spin-out based on Professor Colin Caro's research linking vessel geometry and blood flow mechanics to vascular disease, the device is engineered to impart a gentle helical shape to the stented femoropopliteal artery, promoting swirling blood flow and elevated wall shear stress that reduce intimal hyperplasia and stent fracture risk. The company's clinical evidence base, including the MIMICS-2 IDE study, MIMICS-RCT, and MIMICS-3D European Registry covering over 1,750 patients, supports outcomes comparable to drug-eluting devices without paclitaxel exposure. BioMimics 3D holds regulatory approvals in the US (FDA PMA), Europe (CE Mark), and Japan (Shonin). Since its December 2018 acquisition by Otsuka Medical Devices Co., Ltd., Veryan has operated as a wholly-owned subsidiary of Otsuka Holdings with offices in Horsham, UK, and an R&D Innovation Centre in Galway, Ireland.

The company sells directly via dedicated sales teams in Germany and the United States and through an established distributor network across 19 European countries plus selected international markets including China, Chile, the UAE, and Israel. In the United States, Veryan holds a Premier, Inc. group purchasing agreement (effective May 2022) providing pre-negotiated access to Premier member hospitals. The company also distributes the Revolution Peripheral Atherectomy System in the US through a partnership with Rex Medical, extending its peripheral vascular portfolio. Revenue is generated through unit-priced hardware sales of stent devices and related accessories to vascular surgeons and interventional cardiologists treating symptomatic peripheral arterial disease in femoropopliteal lesions. Customer engagement emphasizes clinical evidence presentations at vascular conferences, key opinion leader relationships (including MIMICS programme principal investigators), and direct physician interaction rather than traditional marketing-led demand generation.

Leadership is anchored by serial medtech entrepreneur Chas Taylor as CEO, with the executive team bringing prior experience at companies including Endologix, Abbott, CR Bard, Biotronik, and Olympus. With approximately 51-100 employees, the organization is structured to support regulatory, clinical, commercial, and R&D functions across its two operating geographies. Veryan does not disclose revenue as a non-listed subsidiary of Otsuka Holdings, and operates under the medical device quality and regulatory regimes of its three primary commercial jurisdictions.

Name

Veryan Medical

Legal name

Veryan Medical Limited

Website

https://veryanmed.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Veryan Medical Limited develops and commercializes the BioMimics 3D Vascular Stent System, a 3D helical nitinol peripheral stent for femoropopliteal interventions, serving vascular surgeons and interventional cardiologists across the US, Europe, and Japan as a subsidiary of Otsuka Medical Devices.

Ownership category

akta.pro rank

Product category

Peripheral Vascular Stents

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

akta.pro secondary industry

Vascular Medicine (Peripheral Arterial/Venous Disease) (HLAKABAG)

Keywords

• Vascular stent systems
• Peripheral vascular devices
• Biomimetic stent technology
• Endovascular intervention products
• Femoropopliteal artery stenting

Headquarters

HQ city

Horsham

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: Veryan generates revenue through the sale of its BioMimics 3D Vascular Stent System and related medical devices. The company sells directly in Germany and US through specialized sales teams, and through distributor networks in other international markets.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Veryan Medical develops, manufactures, and commercializes the BioMimics 3D Vascular Stent System, a peripheral self-expanding nitinol stent with a unique 3D helical centerline geometry designed for endovascular intervention in patients with symptomatic peripheral arterial disease of the femoropopliteal artery. The product is sold directly in Germany and the US and through distributors across 19+ European countries plus international markets. The company also distributes the Revolution Peripheral Atherectomy System in the US through a partnership with Rex Medical.

Product overview

Veryan Medical is a medical device company specializing in vascular intervention products. The company's primary product is the BioMimics 3D® Vascular Stent System, a peripheral self-expanding nitinol stent featuring a unique 3D helical design that promotes swirling blood flow. Veryan also distributes the Revolution™ Peripheral Atherectomy System in the US market. The BioMimics 3D stent has received regulatory approvals including FDA Premarket Approval (US), CE Mark (Europe), and Shonin (Japan).

Differentiator

Problem solved

Functional benefit

Brands

• BioMimics 3D: BioMimics 3D Vascular Stent System — a peripheral self-expanding nitinol stent with a unique 3D helical geometry designed to impart natural curvature to the femoropopliteal artery, promoting swirling blood flow and elevating wall shear stress to reduce intimal hyperplasia and improve clinical outcomes.
• Revolution

Products and services

• BioMimics 3D Vascular Stent System A peripheral self-expanding nitinol vascular stent with a unique 3D helical centerline geometry designed to impart natural curvature to the diseased femoropopliteal artery. The 3D helical shape is laser-cut from a straight nitinol tube and stored in nitinol shape memory. Promotes swirling blood flow and elevated wall shear stress to reduce intimal hyperplasia. Available in stent diameters of 5, 6, and 7 mm and lengths of 60, 80, 100, 125, and 150 mm. Three tantalum radiopaque markers at each end aid placement; over-the-wire delivery system with 113cm working length. Indicated for endovascular intervention in patients with symptomatic peripheral arterial disease (PAD) in the superficial femoral artery and proximal popliteal artery.
• Revolution Peripheral Atherectomy System A peripheral atherectomy solution with active aspiration and bi-directional cutting capabilities designed for treating peripheral vascular disease. Distributed by Veryan Medical in the United States under a distribution partnership with Rex Medical; features active aspiration and bi-directional cutting for plaque removal in peripheral vascular interventions.

Quantifiable outcome

• KM Freedom from loss of Primary Patency: 83% at 1 year (MIMICS-2)
• +6 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 May 2022Veryan Medical Inc. was awarded a group purchasing agreement for Peripheral and Biliary Stents with Premier, Inc., effective May 1, 2022. The agreement allows Premier members to access special pricing and terms pre-negotiated by Premier for the BioMimics 3D Vascular Stent System in the US market.
• Rex MedicalcoreChannel Partner/ Reseller/ DistributorVeryan Medical entered into a distribution partnership with Rex Medical to distribute the Revolution Peripheral Atherectomy System in the US market. The collaboration demonstrates Veryan's commitment to providing innovative and differentiated therapies. The Revolution system features active aspiration and bi-directional cutting for peripheral vascular disease treatment.
• European Distributor NetworkcoreChannel Partner/ Reseller/ DistributorVeryan maintains a robust commercial presence across 19 European countries via an experienced distributor network including: Austria (Biomedica Medizinprodukte), Lithuania (Septeka), Slovakia (Adyton Medical), Denmark/Finland (CardiRad), Czech Republic (INLAB), Italy (ab medica), Spain (Lexel), Ireland/Northern Ireland (Uniphar Medtech), Great Britain (Macromed UK), Serbia (Austro Line), Israel (Neopharm), Greece (Zerono), Cyprus (Adelmed), Turkey (Gama Medikal), Netherlands/Belgium (ScoVas).
• Shanghai MicroPort Endovascular MedTechminorChannel Partner/ Reseller/ DistributorDistributor for BioMimics 3D Vascular Stent System in People's Republic of China. Shanghai MicroPort Endovascular MedTech is a leading domestic medical device company in China.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Global medical device leader with a peripheral vascular portfolio including self-expanding nitinol stents (e.g., Complete SE, IN.PACT Admiral DCB) used in the same femoropopliteal artery indication as BioMimics 3D. Directly competes for hospital contracts and physician mindshare.
• Boston Scientific: Major peripheral vascular player with the Eluvia drug-eluting stent and Ranger DCB, competing head-to-head with BioMimics 3D in femoropopliteal intervention. Boston Scientific's DES competes on the same primary patency endpoint where BioMimics 3D claims non-inferior outcomes without Paclitaxel.
• Abbott: Diversified medical device incumbent offering peripheral vascular solutions (e.g., XIENCE family of stents, suprapubic and peripheral devices). Competes with Veryan across vascular surgery and interventional cardiology purchasing decisions.
• BD (Bard Peripheral Vascular): BD's Peripheral Vascular division (formerly C.R. Bard) sells a broad peripheral stent portfolio including the LifeStent and LUTONIX DCB. Bard is also closely tied to Veryan's management alumni (multiple executives worked at Bard Cardiovascular).
• Cordis (Cardinal Health): Cardiovascular and peripheral vascular device manufacturer (formerly part of Johnson & Johnson, now Cardinal Health) offering peripheral stents and DCBs competing with BioMimics 3D in femoropopliteal interventions globally.
• Terumo: Japanese medical device conglomerate with a peripheral vascular portfolio including MISAGO stents and Renzan DCBs. Directly comparable to Veryan given overlapping Japanese commercial ties and peripheral vascular focus.

Direct peers

• Cook Medical: Privately held medical device manufacturer with peripheral vascular stents (e.g., Zilver PTX DES historically, Zilver Flex bare-nitinol) competing in the same femoropopliteal segment as BioMimics 3D.
• W. L. Gore & Associates: Manufacturer of the Viabahn covered stent and other peripheral endovascular devices. Gore competes in the femoropopliteal and SFA segments where BioMimics 3D is positioned, with a focus on long lesions and complex anatomy.

Emerging players

• Surmodics: Developer of drug-coated balloon technology (Surmodics Sundance DCB) targeting peripheral vascular applications. Competes with the combination DCB + BioMimics 3D approach by offering an integrated drug-delivery solution.
• Penumbra: Peripheral vascular company offering the Indigo thrombectomy system and HawkOne atherectomy. Competes in the broader peripheral vascular intervention workflow where Veryan distributes the Revolution atherectomy system.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/veryanmed1

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds7 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Veryan Medical